{
    "nctId": "NCT00467012",
    "briefTitle": "Phase \u2161 Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer",
    "officialTitle": "Phase \u2161 Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 122,
    "primaryOutcomeMeasure": "Safety",
    "eligibilityCriteria": "* At least 20 years old and obtained a written informed consent\n* Advanced breast cancer (Stage\u2163) or Inoperable metastatic breast cancer\n* HER2 negative\n* At least one measurable lesion based on RECIST criteria\n* No previous chemotherapy for metastatic breast cancer",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}